In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

GARFIELD-AF prospective registry - Adverse one-year outcomes for patients newly treated with oral anticoagulants plus antiplatelet therapy after a diagnosis of atrial fibrillation

Session Late Breaking Registry Results 2

Speaker Keith Fox

Congress : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Atrial Fibrillation - Stroke Prevention
  • Session type : Late-Breaking Science
  • FP Number : 5878
15 views
15 views

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Other presentations from this session

Late Breaking Registry Results 2

  • ESC Congress 2018
  • Other
  • Late-Breaking Science
  • 28 August 2018
  • 14:30 - 15:45
session 2018 2018
13

Other presentations from this speaker

no speaker photo speaker

Keith Fox

Manager (Head of department/Section/Senior Researcher/Dean/Director or other), University of Edinburgh,Edinburgh (United Kingdom of Great Britain & Northern Ireland)

46


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are